In the news

Posts tagged ViroCell

Hired and retired: New appointments in the biopharma industry

Hired and retired: New appointments in the biopharma industry

Florence BuchananDecember 2, 2022CDMO, UK CDMO, ViroCell, gene therapy, cell and gene therapies, cell therapy, viral vector, viral vectors, New hires, Nick Maishman

ViroCell strengthens senior management team with appointment of Nick Maishman as COO

ViroCell strengthens senior management team with appointment of Nick Maishman as COO

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (“COO”).

ViroCell, an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”), is today addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

In the NewsFlorence BuchananNovember 22, 2022viral vectors, UK CDMO, CDMO, gene therapy, cell therapy, clinical trials, cell and gene therapies, Nick Maishman, ViroCell, Pharmiweb.com

ViroCell names Susan Nichols as CBO

ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO).

The firm is seeking to address the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies by focussing on the design and GMP manufacture of viral vectors…

In the NewsFlorence BuchananSeptember 20, 2022UK CDMO, CDMO, gene therapy, cell therapy, cell and gene therapies, clinical trials, viral vectors, Susan B Nichols, ViroCell, The Pharma Letter

ViroCell Announces the Appointment of Susan B. Nichols as CBO

ViroCell Announces the Appointment of Susan B. Nichols as CBO

ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.

In the NewsFlorence BuchananSeptember 20, 2022UK CDMO, gene therapy, cell therapy, ViroCell, Pharmtech Focus, clinical trials, cell and gene therapies, CDMO, Susan B Nichols, viral vectors

Gene therapy ‘factory’ to save children

Gene therapy ‘factory’ to save children

A new “factory” that will produce benign viruses for Great Ormond Street Hospital is expected to accelerate the development of life-saving gene therapy drugs.

The facility, which is based in the hospital and operated by the biotech company ViroCell Biologics, will more than double Britain’s capacity to manufacture a key type of gene therapy.

Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

ViroCell Biologics confirms a new agreement to address the worldwide viral vector market for clinical trials.

Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

Great Ormond Street Hospital (GOSH) has partnered with manufacturer ViroCell Biologics in an effort to address the global viral vector manufacturing bottleneck for clinical trials.

In the NewsFlorence BuchananOctober 11, 2021CDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, European Pharmaceutical Manufacturer, UK CDMO, ViroCell, Matthew Shaw, CEO at Great Ormond Street Hospital

ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), a world leading children’s hospital, have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.

ViroCell Biologics and GOSH to address gene and cell therapy “logjam”

ViroCell Biologics and GOSH to address gene and cell therapy “logjam”

ViroCell Biologics and Great Ormond Street Hospital (GOSH) partner to tackle the viral vector manufacturing bottleneck for clinical trials.

In the NewsFlorence BuchananSeptember 28, 2021CDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, UK CDMO, ViroCell, Great Ormond Street Hospital, European Pharmaceutical Review, EPR

ViroCell Announces new Board appointments

ViroCell Announces new Board appointments

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of J. David Enloe, Jr. to its Board of Directors and Martin Pule, MD, PhD to its Scientific Advisory Board, both leaders in their respective fields.

ViroCell Announces New Board Appointments

ViroCell Announces New Board Appointments

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of J. David Enloe, Jr. to its Board of Directors and Martin Pule, MD, PhD to its Scientific Advisory Board, both leaders in their respective fields.

ViroCell released in the UK to make viral vectors

ViroCell released in the UK to make viral vectors

ViroCell will supply viral vectors and genetically modified cells to academic and corporate customers for translational cell and gene therapy entering clinical trials.

Global Roundup. Elsewhere across the globe: ViroCell Biologics

Global Roundup. Elsewhere across the globe: ViroCell Biologics

ViroCell Biologics – U.K.-based ViroCell launched with the goal to become the supplier of choice for viral vectors and gene-modified cells. Viral vectors are the primary delivery method for many innovative vaccines.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, BioSpace, UK CDMO, ViroCell, gene therapy, cell therapy, viral vector, vector design, AAV vectors, lentivirus vectors, Farzin Farzaneh

First UK-based clinical trial manufacturer focused on viral vectors announces launch

First UK-based clinical trial manufacturer focused on viral vectors announces launch

ViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, CCR, Complete Clinical Research, gene therapy, cell therapy, vector design, AAV vectors, lentivirus vectors, UK CDMO, ViroCell, Edi Truell

First UK-based clinical trial focused viral vector manufacturer announces launch

First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the primary clinical trial focused viral vector manufacturer within the UK, has introduced its official launch, with the intention of turning into the ‘supplier of choice’ for viral vectors and gene modified cells.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, ViroCell, Farzin Farzaneh, Truell Conservation Foundation, John Hadden II, gene therapy, cell therapy, CGT, UK CDMO, UR ALL news, vector design, AAV vectors, lentivirus vectors

Introducing ViroCell Biologics. The UK’s first clinical trial focused viral vector manufacturer.

Introducing ViroCell Biologics. The UK’s first clinical trial focused viral vector manufacturer.

ViroCell Biologics, founded in the UK by a prolific academic viral vector manufacturing team, has officially launched. Viral vectors are the primary delivery method for innovative vaccines such as the Oxford/Astra Zeneca COVID vaccine, as well as enabling inputs for the manufacture of the rapidly growing Cell and Gene Therapy sector (CGT).

In the NewsFlorence BuchananApril 28, 2021CDMO, ViroCell, viral vector, viral vectors, AAV vectors, lentivirus vectors, gene therapy, cell therapy, CGT, Farzin Farzaneh, John W. Hadden II, Contract Pharma, UK CDMO, vector design

First UK-based clinical trial focused viral vector manufacturer announces launch

First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.

In the NewsFlorence BuchananApril 28, 2021CDMO, ViroCell, Truell Conservation Foundation, Farzin Farzaneh, John Hadden II, gene therapy, cell therapy, CGT, viral vector, viral vectors, vector design, AAV vectors, lentivirus vectors, UK CDMO, PharmaJobs

Edi Truell leads financing of gene therapy start-up ViroCell Biologics

Edi Truell leads financing of gene therapy start-up ViroCell Biologics

Edi Truell is backing a gene and cell therapy start-up and is seeking to lead a £100 million financing as part of his latest venture.

In the NewsFlorence BuchananApril 12, 2021Edi Truell, gene therapy, cell therapy, CDMO, UK CDMO, viral vector, viral vectors, AAV vectors, lentivirus vectors, ViroCell, The Times, Farzin Farzaneh, John W. Hadden II, Truell Conservaton Foundation, Danny Truell, Syncona